(CMRX) Chimerix - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US16934W1062
CMRX: Cancer, Brain Tumor, Neuroendocrine Tumor, Antiviral
Chimerix, Inc. (NASDAQ:CMRX) is a biopharmaceutical company focused on developing innovative antiviral and oncology therapies. Its lead candidate, ONC201, is in Phase 3 trials for H3 K27M-mutant diffuse glioma and Phase 2 for rare neuroendocrine tumors. ONC206, a first-in-class DRD2 antagonist and ClpP agonist, is in Phase 1 for primary CNS tumors. The pipeline also includes ONC212, targeting GPR132, and CMX521, a nucleoside analog for SARS-CoV-2. Chimerix has a license agreement with SymBio Pharmaceuticals for TEMBEXA, excluding smallpox applications. Incorporated in 2000, the company is based in Durham, North Carolina.
Chimerixs pipeline emphasizes first-in-class therapeutics, addressing unmet needs in oncology and antiviral treatments. Their approach combines a deep understanding of tumor biology with innovative drug development, focusing on rare and deadly diseases. The companys strategic partnerships, like with SymBio, enhance its commercialization capabilities, particularly for TEMBEXA.
3-Month Forecast: Based on
Additional Sources for CMRX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CMRX Stock Overview
Market Cap in USD | 758m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2013-04-11 |
CMRX Stock Ratings
Growth 5y | 23.3% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | 703 |
Analysts | 4.8/5 |
Fair Price Momentum | 7.55 USD |
Fair Price DCF | - |
CMRX Dividends
No Dividends PaidCMRX Growth Ratios
Growth Correlation 3m | 97.4% |
Growth Correlation 12m | 40.1% |
Growth Correlation 5y | -66.3% |
CAGR 5y | 43.02% |
CAGR/Max DD 5y | 0.46 |
Sharpe Ratio 12m | -0.02 |
Alpha | 646.46 |
Beta | -1.32 |
Volatility | 67.19% |
Current Volume | 2242k |
Average Volume 20d | 2138.2k |
As of March 16, 2025, the stock is trading at USD 8.46 with a total of 2,241,975 shares traded.
Over the past week, the price has changed by +0.36%, over one month by +93.15%, over three months by +190.72% and over the past year by +642.11%.
Neither. Based on ValueRay Analyses, Chimerix is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 23.26 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CMRX as of March 2025 is 7.55. This means that CMRX is currently overvalued and has a potential downside of -10.76%.
Chimerix has received a consensus analysts rating of 4.80. Therefor, it is recommend to buy CMRX.
- Strong Buy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CMRX Chimerix will be worth about 8.2 in March 2026. The stock is currently trading at 8.46. This means that the stock has a potential downside of -3.66%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 8.5 | 0.9% |
Analysts Target Price | 8.4 | -0.7% |
ValueRay Target Price | 8.2 | -3.7% |